Better drug development

Previously inaccessible insights, unlocked by our proprietary CDM technology, will enable more targeted, efficient drug development.

Select AD

Using CDM® we will optimise patient selection, combine other clinical and patient demographics, and positively impact trial costs and performance. CDM® can estimate a patient’s pathology disease stage using grey matter quality. We provide a likelihood that a patient will progress to the next stage of disease within the next few years.

Track AD

We can provide longitudinal patient results based on changes across baseline and time points in accordance with your clinical trial protocol. Grey matter quality changes can also be provided in brain visualisations over multiple time periods. We can provide our results based on whole brain, brain regions and even sub regions if required.


Personalised insights for patients

Our technology will help to support clinicans striving for a more accurate diagnosis, prediction of change and personalised management of neurodegenerative conditions.

Supporting patient care

Unlocking novel information for doctors from MRI scans enables a more personalised treatment, giving hope to patients. Quantifying & Visualising brain changes using CDM® can support improved communications between doctors, patients and their carers.

Helping clinicans in their diagnosis

By providing novel information from standard MRI scans, we hope to support clinicans who experience uncertainty in diagnosing neurodegenerative conditions. Cortical Disarray Measurement (CDM) software has been granted Breakthrough Device designation by the FDA and our first product is under review awaiting 510K clearance. 

Differential patterns of brain changes

By mapping neurodegenerative conditions and their progression across different regions of the brain, CDM potentially reveals different disease patterns based on cell structure. In research publications, CDM has identified different patterns of neurodegeneration in the brain in atypical Alzheimer’s disease (posterior cortical atrophy) and fronto-temporal dementia.

Accurately tracking changes

Our insights into the micro-structure of the brain, will help clinicians track and accurately predict the course of neurodegenerative conditions in the future. CDM measures are designed to detect altered quality of grey matter tissue composition in patients. Our research into MCI also supports using (CDM) for identification of the early stages of Alzheimer’s disease.

Proactive Brain Health

Identifying and tracking changes based on the brain’s cellular structure enables clinicians to offer personalised treatment and actively promote brain health throughout a lifetime.